VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy

REQUEST A REP
Click Here
Request a Rep
The first and only FDA-approved topical formulation of mechlorethamine (commonly known as nitrogen mustard)

Welcome to the VALCHLOR Interactive Learning Module!

Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) is difficult to identify. Undiagnosed MF-CTCL patients often experience years of skin-directed treatments.1 In fact, the majority of these patients have been using topical corticosteroids prior to diagnosis.2,3 The path to diagnosis can take months or years,4 and early diagnosis is important.

Learn more about early stage MF-CTCL and VALCHLOR.

Start Now. Click on any marker Start Now click on any marker
Navigate the challeneges
Navigate

the challenges of stage

IA and IB MF-CTCL

Identify Treat Support

Please see Important Safety Information below and full Prescribing Information.

References
Expand
Close

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VALCHLOR is contraindicated in patients with known severe hypersensitivity to mechlorethamine. Hypersensitivity reactions, including anaphylaxis, have occurred with topical formulations of mechlorethamine.

WARNINGS AND PRECAUTIONS

  • Mucosal or eye injury: Exposure of mucous membranes to mechlorethamine such as the oral mucosa or nasal mucosa causes pain, redness, and ulceration, which may be severe. Exposure of the eyes causes pain, burns, inflammation, photophobia, and blurred vision. Blindness and severe irreversible anterior eye injury may occur. Should eye exposure or mucosal contact occur, immediately irrigate for at least 15 minutes with copious amounts of water, followed by immediate medical consultation
  • Secondary exposure: Avoid direct skin contact with VALCHLOR in individuals other than the patients due to risk of dermatitis, mucosal injury, and secondary cancers
  • Dermatitis: Dermatitis may be moderately-severe or severe. Monitor patients for redness, swelling, inflammation, itchiness, blisters, ulceration, and secondary skin infections. Stop treatment with VALCHLOR or reduce dose frequency
  • Non-melanoma skin cancer: Monitor patients during and after treatment with VALCHLOR
  • Embryo-fetal toxicity: Women should avoid becoming pregnant while using VALCHLOR due to the potential hazard to the fetus. For nursing mothers, discontinue use of VALCHLOR or nursing
  • Flammable gel: VALCHLOR is an alcohol-based gel. Avoid fire, flame, and smoking until the gel has dried

ADVERSE REACTIONS

The most common adverse reactions (≥5%) were dermatitis (56%), pruritus (20%), bacterial skin infection (11%), skin ulceration or blistering (6%), and hyperpigmentation (5%). These reactions may be moderately-severe or severe. Elderly patients aged 65 and older may be more susceptible. Depending on severity, treatment reduction, suspension, or discontinuation may be required.

DOSING AND APPLICATION

VALCHLOR is for topical dermatological use only. Apply a thin film once daily to affected areas of the skin. Caregivers must wear disposable nitrile gloves when applying VALCHLOR. Patients and caregivers must wash hands thoroughly after handling or applying VALCHLOR.

To report SUSPECTED ADVERSE REACTIONS, contact Actelion Pharmaceuticals US, Inc., at 1-855-4-VALCHLOR (1-855-482-5245) or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see VALCHLOR full Prescribing Information.

Actelion
VALCHLOR® and VALCHLOR Support™ are trademarks of Actelion Pharmaceuticals Ltd
All other trademarks and registered trademarks are the property of their respective owners.
©2017 Actelion Pharmaceuticals US, Inc.       All rights reserved.     VAL-00505       0917
Valchlon